Deliver Your News to the World

C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe

OncoDNA’s Lab in France is the first in the EU to enable access to the C2inform test for clinical decision making


C2i Genomics, a cancer intelligence company, today announced the next stage in its partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases.

“Expanding our partnership with C2i Genomics’ and our IntegraGen lab in France, C2inform testing is now available for patients in the EU over the age of 18 with solid organ cancers. The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test. Clinicians can order the C2inform test through our OncoShare platform,” said Jean-Pol Detiffe, Founder, Chief Strategy & Innovation Officer at OncoDNA.

The C2inform test applies whole-genome sequencing and C2i’s state-of-the-art cancer data analysis to a 4 mL blood sample to support the rapid and accurate detection of moleular residual disease (MRD) to monitor disease progression, evaluate therapeutic efficacy and detect cancer recurrence. The test allows for informed and timely personalized treatment decisions for cancer patients across the EU.

“As we continue to pave the way for precision medicine in the fight against cancer, we are proud to enter the next stage in our partnership with OncoDNA,” said Ezra Sofer, CEO and co-founder of C2i Genomics. “This launch of our C2inform test in Europe is a testament to our commitment to improving patient outcomes through innovative and personalized cancer diagnostics and our goal to have our test available for cancer patients in the clinic at an affordable price.”

The timely assessment of MRD enables:

  • Risk Stratification: Informing whether patients need additional cancer treatment and assessing whether post-neoadjuvant therapy, post-surgery, or post-adjuvant therapy is required.
  • Therapeutic Monitoring: Determining if the patient’s current treatment is working.
  • Recurrence Monitoring: Monitoring for recurrence even after the patient is cleared of a tumor.

C2inform has proven to better serve as a prognostic biomarker to guide the course of treatment toward either an organ-sparing watch-and-wait protocol or surgical resection.

Additionally, C2i Genomics is excited to strengthen the partnership with OncoDNA for a notable clinical trial conducted by a leading European cancer research institution in partnership with a prominent pharmaceutical industry leader.

This strategic alliance will leverage C2i Genomics’ MRD solution alongside OncoDNA’s essential lab management and sample processing expertise, eliminating the need to develop a patient-specific assay, and enabling high-performance, personalized monitoring and rapid turnaround across multiple solid cancers with reduced operational complexity.

Companies interested in deploying C2inform or learning more about C2i Genomics can visit

About C2i Genomics:
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. C2i was named to the 2021 CB Insights Digital 150 list and awarded the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by Frost & Sullivan. For more information, please visit

About OncoDNA:
OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories. For further information, visit and connect with us on LinkedIn, Facebook or Twitter.

( Press Release Image: )


 C2i Genomics
 Whole Genome

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.